Skip to the beginning of the images gallery

Sugemalimab (anti-PD-L1) - Primary antibody, specific to CD274, >95%, high purity, Human IgG4SP, BINDING AGENT of Programmed cell death 1 ligand 1 binding agent

Azide Free
Carrier Free
ExactAb™
Low Endotoxin
Recombinant
Validated
≥95%(SDS-PAGE&SEC)
Lot by Lot

Features and benefits

Short Overview:
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Species reactivity(Reacts with): Human
Isotype: Human IgG4SP

Application:

Animal Model
ELISA
Flow Cytometry
Functional Assay

Item Number

Ab175662

Grouped product items
SKU	Size	Availability	Price
Ab175662-100μg	100μg	In stock	$149.90
Ab175662-1mg	1mg	In stock	$709.90
Ab175662-5mg	5mg	In stock	$1,779.90
Ab175662-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$2,849.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series

Accession#:Q9NZQ7 Cd274 Gene ID:29126 PD-L1

Basic Description

Product Name	Sugemalimab (anti-PD-L1) - Primary antibody, specific to CD274, >95%, high purity, Human IgG4SP
Synonyms	B7 H antibody; B7 H1 antibody; B7 homolog 1 antibody; B7-H1 antibody; B7H antibody; B7H1 antibody; CD 274 antibody; CD-274 antibody; CD274 antibody; CD274 antigen antibody; CD274 molecule antibody; MGC142294 antibody; MGC142296 antibody; OTTHUMP0000002102
Specifications & Purity	ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Specificity	CD274
Conjugation	Unconjugated
Grade	Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type	BINDING AGENT
Mechanism of action	BINDING AGENT of Programmed cell death 1 ligand 1 binding agent
Product Description	Sugemalimab (anti-PD-L1) is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab (anti-PD-L1) shows anticancer activities and can be used for non-small cell lung cancer research.

Product Properties

Isotype	Human IgG4SP
Light Chain Type	lambda
SDS-PAGE	27.2 kDa (Light Chain) & 51.2 kDa (Heavy Chain), under reducing conditions; 183.8 kDa, under non-reducing conditions.
Purification Method	Protein A purified
Purity	>95%
Form	Liquid
Concentration	Lot by Lot
Storage Temp	Store at -80°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS	2256084-03-2

Images

Sugemalimab (anti-PD-L1) (Ab175662) - Flow Cytometry
Flow Cytometry analysis of 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated Jurkat cells (24h) labelling PD-L1 (red) with Sugemalimab (anti-PD-L1) (Ab175662). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Sugemalimab (anti-PD-L1) (Ab175662) - SEC
The purity of Sugemalimab (anti-PD-L1) (Ab175662) is more than 95% verified by HPLC.

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

3 results found

Lot Number	Certificate Type	Date	Item
ZJ24F0404392	Certificate of Analysis	Apr 10, 2024	Ab175662
ZJ24F0404391	Certificate of Analysis	Apr 10, 2024	Ab175662
ZJ24F0404390	Certificate of Analysis	Apr 10, 2024	Ab175662

References

1. Dhillon S, Duggan S. (2022) Sugemalimab: First Approval.. Drugs, 82 (5): (593-599). [PMID:35298827]
2. Gong J, Cao J, Zhang Q, Xu N, Zhao Y, Xing B, Miao Z, Wu Y, Pan H, Gao Q et al.. (2022) Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.. Cancer Immunol Immunother, 71 (8): (1897-1908). [PMID:34984540]
3. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al.. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.. N Engl J Med, 369 (2): (134-44). [PMID:23724846]
4. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC et al.. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.. J Exp Med, 192 (7): (1027-34). [PMID:11015443]
5. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. (2017) Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.. Sci Rep, 7 (1): (5532). [PMID:28717238]
6. Lin DY, Tanaka Y, Iwasaki M, Gittis AG, Su HP, Mikami B, Okazaki T, Honjo T, Minato N, Garboczi DN. (2008) The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.. Proc Natl Acad Sci USA, 105 (8): (3011-6). [PMID:18287011]
7. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA. (2015) Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.. Structure, 23 (12): (2341-2348). [PMID:26602187]
8. Cheng B, Ren Y, Niu X, Wang W, Wang S, Tu Y, Liu S, Wang J, Yang D, Liao G, Chen J.. (2020) Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.. J Med Chem, 63 (15): (8338-8358). [PMID:32667799]
9. He, Xian-hui XH, Xu, Li-hui LH and Liu, Yi Y.. (2005) Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain.. Acta pharmacologica Sinica, [PMID:15780196]
10. Rosenberg, Jonathan E JE and 30 more authors.. (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.. Lancet (London, England), (7): [PMID:26952546]
11. Kataoka, Keisuke K and 43 more authors.. (2016) Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.. Nature, (16): [PMID:27281199]
12. and Markham, Anthony A.. (2016) Atezolizumab: First Global Approval.. Drugs, [PMID:27412122]
13. Bellmunt, Joaquin J, Powles, Thomas T and Vogelzang, Nicholas J NJ.. (2017) A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.. Cancer treatment reviews, [PMID:28214651]
14. Mezzadra, Riccardo R and 18 more authors.. (2017) Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.. Nature, (7): [PMID:28813410]
15. Burr, Marian L ML and 23 more authors.. (2017) CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.. Nature, (7): [PMID:28813417]
16. Faiena, Izak I and 5 more authors.. (2018) Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.. Drug design, development and therapy, [PMID:29416316]
17. Dong, H H, Zhu, G G, Tamada, K K and Chen, L L.. (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.. Nature medicine, [PMID:10581077]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

Sugemalimab (anti-PD-L1) - Primary antibody, specific to CD274, >95%, high purity, Human IgG4SP, BINDING AGENT of Programmed cell death 1 ligand 1 binding agent

Basic Description

Product Properties

Images

Associated Targets

CD274 Tclin Programmed cell death 1 ligand 1 0 Activities

Database links